Open-label proof-of-concept trial (n=12) of two psilocybin sessions (25 mg then 25 mg or 35 mg) with psychological support for treatment-seeking people with Cannabis Use Disorder across a 12‑week course.
This pilot, single-group study will test whether two supervised psilocybin sessions delivered within a 12-week counselling programme reduce cannabis use in 12 participants with Cannabis Use Disorder.
Participants complete four weekly preparatory meetings including a targeted CBT intervention, a psilocybin session (25 mg) in week 5 and a second session (25 mg or 35 mg) in week 7, with integration meetings and weekly follow-up through week 12 and assessments at 3 and 6 months.
Open-label two psilocybin dosing sessions with psychological support approximately 2 weeks apart within a 12-week counselling course.
25 mg in week 5; second session in week 7 at 25 mg or 35 mg.